Sequencing therapies for metastatic renal cell carcinoma
Künye
Dizman, N., Arslan, Z. E., Feng, M. ve Pal, S. K. (2020). Sequencing therapies for metastatic renal cell carcinoma. Urologic Clinics of North America, 47(3), 305-318. https://dx.doi.org/10.1016/j.ucl.2020.04.008Özet
In an era of several therapeutic options available, optimal treatment sequencing is crucial to providing patients the most effective therapy and promoting quality of life. In clear cell renal cell carcinoma, a combination approach with an immunotherapy backbone, such as nivolumab/ipilimumab or axitinib/pembrolizumab, has a key role in the first-line setting. Safety and activity data support the transition to single-agent targeted therapies in the second-line setting. Nivolumab monotherapy possesses clinical and mechanistic rationale as a second-line therapeutic option for patients treated with targeted therapies in the first-line setting. Gene expression models are being generated from large prospective clinical trial data sets.
WoS Q Kategorisi
Q3Scopus Q Kategorisi
Q2Kaynak
Urologic Clinics of North AmericaCilt
47Sayı
3Koleksiyonlar
- Makale Koleksiyonu [3452]
- PubMed İndeksli Yayınlar Koleksiyonu [3764]
- Scopus İndeksli Yayınlar Koleksiyonu [5808]
- WoS İndeksli Yayınlar Koleksiyonu [5978]